ENB Lead Product ENB001 Awarded Orphan Drug Designation by the FDA

January 21,2016- FDA awards ENB lead product ENB001 Orphan Drug Designation for Stage IIB- Stage IV melanoma. This represents a major milestone in our development program for ENB001 which now qualifies for various development incentives including tax credits for clinical trials, seven year marketing exclusivity in the US following approval, and a fast track for the FDA to evaluate registration files.

Submit a Comment

Your email address will not be published. Required fields are marked *